| Severe asthma (n = 5) | Healthy control (n = 3) |
---|---|---|
Age (years) | 43 ± 17 | 38 ± 15 |
Sex (Female: Male) | 4:1 | 2:1 |
Race (n) | ||
 Caucasian | 3 | 1 |
 African-American | 0 | 1 |
 Asian | - | 1 |
 Other | 2 | 0 |
 Hispanic (n) | 3 | 1 |
 BMI (Kg/m2) | 36 ± 6 | 23 ± 4 |
 Smoking (n) | 2 | 0 |
 Pack years | 1 each | - |
Therapies % (n) | ||
 Inhaled corticosteroids | 100 (5) | - |
 Long-acting β2-agonist | 100 (5) | - |
 Montelukast | 60 (3) | - |
 Tiotropium | 40 (2) | - |
 Omalizumab | 20 (1) | - |
 FEV1 pre-bronchodilator (% Predicted) | 80 ± 18 | 91 ± 7 |
 FEV1/FVC | 78 ± 5 | 82 ± 14 |
 FeNO (ppb) | 23 ± 14 | 23 ± 16 |
 Absolute blood eosinophils (cells/microliter) | 260 ± 196 | 6 ± 11 |